10-QPeriod: Q1 FY2012

AXON ENTERPRISE, INC. Quarterly Report for Q1 Ended Mar 31, 2012

Filed May 10, 2012For Securities:AXON

Summary

TASER International, Inc. (now Axon Enterprise, Inc.) reported a significant improvement in financial performance for the first quarter of 2012 compared to the same period in 2011. Net sales increased by 10.9% to $25.6 million, primarily driven by strong adoption of the TASER X2 and increased sales of the X26 ECDs, including a significant order from the U.S. Army. The company also saw improved gross margins, rising to 59.4% from 52.8%, attributed to manufacturing efficiencies and a favorable product mix in the ECD segment. This operational improvement, combined with reduced litigation judgment expenses due to a favorable court ruling in the Turner case, led to a substantial increase in net income to $3.8 million ($0.07 per share) from a nominal $0.02 million ($0.00 per share) in the prior year. Cash flow from operations remained robust, providing $3.7 million, supporting a healthy cash balance of $29.7 million in cash, cash equivalents, and investments. The company also announced a new $20.0 million share repurchase program, signaling confidence in its financial position and future prospects. Despite ongoing litigation, the company appears to be navigating these challenges effectively, with a strong operational turnaround and positive financial outlook for the near term.

Financial Statements
Beta

Key Highlights

  • 1Net sales increased by 10.9% to $25.6 million in Q1 2012 compared to Q1 2011, driven by strong ECD segment performance, particularly the TASER X2.
  • 2Gross margin improved significantly to 59.4% from 52.8% in the prior year's quarter, indicating enhanced manufacturing efficiencies and a favorable product mix.
  • 3Net income surged to $3.8 million ($0.07/share) from $0.02 million ($0.00/share) in Q1 2011, boosted by increased sales, improved margins, and a $2.2 million benefit from a litigation judgment reversal.
  • 4Cash provided by operating activities was $3.7 million, contributing to a healthy cash, cash equivalents, and investments balance of $29.7 million as of March 31, 2012.
  • 5A new $20.0 million share repurchase program was authorized by the Board of Directors, reflecting management's confidence in the company's financial health.
  • 6The company continues to expand its product offerings, with traction seen in the AXON Flex on-officer camera and EVIDENCE.COM management service.
  • 7Despite ongoing litigation, the company reported compliance with its debt covenants and has a strong liquidity position with no outstanding debt.

Frequently Asked Questions

The primary driver of sales growth was the strong adoption of the TASER X2, which contributed $3.2 million in sales. Additionally, sales of TASER X26 ECDs increased, benefiting from a significant order from the United States Army.

Profitability improved significantly due to a combination of factors. Net sales increased, gross margins expanded to 59.4% from 52.8% driven by manufacturing efficiencies and a favorable product mix, and litigation judgment expenses decreased due to a favorable court ruling in the Turner case, resulting in a $2.2 million benefit.

As of March 31, 2012, the company had $29.7 million in cash, cash equivalents, and investments. Net cash provided by operating activities was $3.7 million. The company believes its current liquidity is sufficient to finance operations and strategic initiatives, and it also has a $10.0 million revolving credit facility available.

The company is involved in several product liability lawsuits. While the Turner case resulted in a reduced jury award that was partially reversed, other appeals are ongoing. The company is defending these lawsuits vigorously, and its insurance coverage is a key factor in assessing financial exposure. For other pending litigation, the company is in various stages of discovery, motion, or pleading phases.